X-linked myopathy with excessive autophagy (XMEA) is a childhood-onset disease characterized by progressive vacuolation and atrophy of skeletal muscle. We show that XMEA is caused by hypomorphic alleles of the VMA21 gene, that VMA21 is the diverged human ortholog of the yeast Vma21p protein, and that like Vma21p it is an essential assembly chaperone of the V-ATPase, the principal mammalian proton pump complex. Decreased VMA21 raises lysosomal pH, which reduces lysosomal degradative ability and blocks autophagy. This reduces cellular free amino acids, which upregulates the mTOR pathway and mTOR-dependent macroautophagy, resulting in proliferation of large and ineffective autolysosomes that engulf sections of cytoplasm, merge together, and vacuolate the cell. Our results uncover macroautophagic overcompensation leading to cell vacuolation and tissue atrophy as a mechanism of disease.
INTRODUCTION
V-ATPases are ubiquitous in endomembrane systems of all cells and are also present at the plasma membrane of specialized cells that secrete acid. They are proton pumps that acidify lysosomes and regulate the pH of multiple cell systems, including the secretory pathway and the endovesicular system, which use gradated pH to accomplish stepwise modifications. The V-ATPase is composed of 13 subunits organized into a transmembrane (V 0 ) and a cytoplasmic (V 1 ) sector and has a unique rotary pumping mechanism (Figure S1 available online) (Forgac, 2007) . In yeast, assembly of the V 0 sector takes place in the endoplasmic reticulum (ER), and a chief chaperone coordinating the process is the Vma21p protein (Malkus et al., 2004) . V-ATPase subunits are highly conserved from yeast to man, but the closest mammalian sequence to Vma21p has less than 22% identity and lacks a dilysine signal important in Vma21p function (Malkus et al., 2004) , making it unclear whether this predicted protein (LOC203547) is indeed the Vma21p ortholog and whether V-ATPase biogenesis in mammals parallels that of yeast. The V-ATPase is vital. To date, all disease-causing mutations in V-ATPase subunits are in specialized subunit isoforms conferring specialized functions to the V-ATPase (Forgac, Cell 137, 235-246, April 17, 2009 ª2009 Elsevier Inc. 235
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2007), e.g., bone resorption by osteoclast plasma membrane V-ATPases. There are no diseases with mutations in the ubiquitous subunits common to all V-ATPases. X-linked myopathy with excessive autophagy (XMEA; MIM 310440) (Kalimo et al., 1988 ) is a skeletal muscle disorder inherited in recessive fashion, affecting boys and sparing carrier females. Onset is in childhood, and patients exhibit weakness of the proximal muscles of the lower extremities, progressing slowly to involve other skeletal muscle groups over time. Other organs including the heart and brain are clinically unaffected. Pathological analysis of skeletal muscle biopsies shows no inflammation, necrosis, or apoptosis. Instead, myofiber demise occurs through a novel form of autophagic cell death. Forty to eighty percent of fibers are diseased, exhibiting giant autophagic vacuoles 2-10 mm in size encircling sections of cytoplasm including organelles, proteins, etc. The vacuoles contain lysosomal hydrolases, yet they are unable to complete digestion of their contents. Instead, they migrate to the myofiber surface, fuse with the sarcolemma, and extrude their contents extracellularly, forming a field of cell debris around the fiber (Figures S1 and S2) (Chabrol et al., 2001; Kalimo et al., 1988; Minassian et al., 2002; Villanova et al., 1995) .
We show that LOC203547 is the human ortholog of Vma21p and that hypomorphic mutations in its gene disrupt autophagy and cause XMEA. XMEA represents an unusual genetic mechanism of disease: a major housekeeping enzyme complex (the V-ATPase) essential to multiple cell systems in all cells is downregulated to only a level affecting to a clinical extent the system with highest dependence on it, autophagy, in the tissue with highest reliance on autophagy, skeletal muscle.
RESULTS
Hypomorphic Mutations in the LOC203547 Gene Cause XMEA We previously mapped the XMEA gene to a 0.58 Mb region of Xq28 containing four known genes and a fifth, LOC203547, predicted on the basis of multiple expressed sequence tags (ESTs) and mRNAs (Munteanu et al., 2008) . We have now sequenced exons and flanking intronic sequences of all five genes in XMEA patients from 14 families and found sequence changes in only LOC203547 ( Figure 1A ). These changes were present in all patients, and in all families segregated with the disease. To confirm that the changes are mutations, we sequenced LOC203547 in over 450 chromosomes from unaffected individuals, including for each mutation $100 chromosomes from ethnically matched controls, none of which had any of the changes (Table S1). LOC203547 has three exons, and a 4.7 Kb transcript expressed in all tissues ( Figures 1A and S3 ). The mutations consist of six different single-nucleotide substitutions (Figures  1A and S4 and Table S1 ). The first two, c.54 À27A/T and c.54 À27A/C, eliminate the A nucleotide predicted to define the first intron's splice branch point. The third, c.163 +4A/G, removes the A in the +4 position after exon 2 that is required for optimal U1 small nuclear RNA (snRNA) binding during splicing. The fourth, c.164 À7T/G, disrupts the polypyrimidine tract in intron 2, which would reduce the U2AF splice factor binding efficiency. A fifth, c.272G/C, is in coding sequence replacing a glycine with alanine, but it also abolishes a predicted splice enhancer site. The sixth, c.*6A/G, is in the 3 0 untranslated region (UTR).
Splice site mutations cause disease by generating abnormal spliceforms or by decreasing mRNA quantity through reduced splicing efficiency. We detected no splice variants, but quantitative RT-PCR (qRT-PCR) in lymphoblasts and fibroblasts revealed 32%-58% reduction in LOC203547 mRNA in all patients, including those with the 3 0 UTR mutations (Figures 1B and 1C) . Western blots and immunocytochemistry showed that LOC203547 is also reduced at the protein level ( Figures 1D  and 1E ). To confirm that these reductions are directly caused by the LOC203547 mutations and are not secondary disease effects, we created minigene constructs for each of the splice site mutations ( Figure S5 ) and expressed them in C2C12 myoblasts. In these experiments, the only difference between patient and control minigenes is the one LOC203547 nucleotide mutated in each patient. qRT-PCR showed >40% decrease in LOC203547 minigene mRNA in patients versus controls (Figures 1F and 1G) , confirming that the mutations that we identified are the cause of the LOC203547 downregulation.
LOC203547 Is the Human Ortholog of the Yeast V-ATPase Assembly Chaperone Vma21p
Toward determining whether LOC203547 is the human ortholog of Vma21p, we first asked whether its downregulation in XMEA affects the V-ATPase, and whether this effect is the same as the previously characterized effect of Vma21p deficiency on the V-ATPase in yeast. The yeast vma21 deletion mutant (vma21D) has drastically reduced V-ATPases and V-ATPase activity in organellar membranes, and defective growth. It also exhibits increased V 1 sector proteins in its cytosol, which occurs because normally V 1 subunits are produced in the cytosol and added later on to the ER-assembled V 0 sector. In vma21D, V 0 assembly fails. As a result, V 1 proteins can no longer find V 0 matches and accumulate in the cytosol (Malkus et al., 2004) . We measured V-ATPase activity in the light membrane fraction (includes all organelles) of XMEA patient lymphoblast extracts and found that it is reduced to 12%-22% of normal ( Figure 2A ). In fibroblasts, V-ATPase activity was reduced to 11%-13% of normal, and in fresh-frozen muscle biopsies to 21%-33% of normal ( Figure 2B ). We next assessed the amount of V-ATPases in the light membrane fractions by performing immunoprecipitation and western blot experiments with antibodies against several V 0 and V 1 components, and we found them all reduced in patients ( Figures 2C and 2D ), indicating that the decreased V-ATPase activity was due to decreased numbers of organellar V-ATPases, which we confirmed by directly counting V-ATPases on intact organelle membranes of intact cells using immunogold electron microscopy (Figures 2E and 2F) . Western blots of cytosolic and light membrane fractions showed that V 1 subunits were increased in patient cytosols by an amount similar to the amount by which they were decreased from their organellar membranes ( Figure 2D ), indicating that the decrease in V-ATPases is due to decreased formation of V 0 complexes.
Next, we showed that LOC203547 directly interacts, within membranes, with V 0 . Immunoprecipitation of LOC203547 from light membrane fractions of control and patient cells after crosslinking and use of detergent C12E9 (which maintains lipid bilayer protein complex integrity) coprecipitated the V 0 complex ( Figures 3A and 3B ). In the absence of crosslinking and C12E9, 
only V 0 subunit c 00 , and not other subunits, coprecipitated with LOC203547 ( Figure 3C ), indicating that the interaction of LOC203547 with V 0 is via subunit c 00 . Finally, we asked whether LOC203547 can complement vma21D. The vma21D yeast strain is characterized by a welldefined set of growth defects including stunted growth on complete media, and lack of growth on media with nonfermentable carbon sources or with elevated pH or calcium (Malkus et al., 2004) . We cultured vma21D, LOC203547-transformed vma21D, and wild-type yeast for 3 days in YP-glycerol (pH 5.5; glycerol as carbon source), YPD (pH 7.5; elevated pH), and YPD (pH 5.5) with 10 mM CaCl 2 . Vma21D showed characteristic negligible growth, while LOC203547-transformed vma21D grew proficiently, and equally to the wild-type, on all three media ( Figure 3D) , showing that LOC203547 fully rescues vma21D.
Collectively, results in this section establish that LOC203547 is the human ortholog of Vma21p. LOC203547 is named VMA21 in the remainder of this paper. (C) Immunoprecipitation, with anti-subunit ''a'' antibody, of protein samples in light membrane fractions of lymphoblasts under nondenaturing conditions with C12E9 detergent and DTSSP crosslinking. Western blotting with the same antibody detects the fully assembled V 0 complex (250 kD), of which subunit ''a'' is a part, and also free subunit ''a'' in the membrane not bound to the complex (116 kD). In patients, there are less V 0 complexes. There is also decreased free subunit ''a,'' because subunit ''a'' molecules not finding binding partners are rapidly degraded (Malkus et al., 2004) . Anti-HA antibody was used as immunoprecipitation control.
(D) V 1 subunit E in patients is decreased from light membrane fractions (Mem) and increased in the cytosolic fraction (Cyt). Band intensities in patients were as follows: c.6*A/G, 0.32 ± 0.14 (Mem) and 1.23 ± 0.24 (Cyt); c.272G/C, 0.44 ± 0.04 (Mem) and 1.36 ± 0.17 (Cyt); c.164-7T/G, 0.27 ± 0.03 (Mem) and 1.42 ± 0.11 (Cyt).
(E and F) Representative electron micrographs of neutrophils from normal (E) and an XMEA case (F) immunogold labeled against subunit ''a.'' In the XMEA patient, gold particle density is reduced from the plasma membrane and from the membranes of neutrophil phagosomes; the scale bar represents 0.5 mm. Actual mean counts from 150 neutrophils from three controls (50 cells per control) and 100 neutrophils from two patients (50 cells per patient) were, in particles/ linear mm, as follows: control plasma membrane, 2.7 ± 0.5; patient plasma membrane, 0.4 ± 0.1; control phagosome membrane, 4.3 ± 0.75; patient phagosome membrane, 1.25 ± 0.06; significance < 0.001 (student's t test).
The Subcellular Stations of VMA21 Diverge from Those of Vma21p
In yeast, Vma21p first interacts in the ER membrane with the V 0 subunit c 0 . This initiates a stepwise assembly of the other V 0 components, and presence of Vma21p is necessary throughout the process. Once V 0 is formed, Vma21p accompanies it on COPII vesicles to the Golgi apparatus, and V 1 subunits are added to complete the V-ATPase (Malkus et al., 2004; Ochotny et al., 2006) . Vma21p is retargeted by its carboxy-terminal dilysine signal to the ER, while each V-ATPase is directed to its particular destination on the basis of which isoform of the V 0 ''a'' subunit was incorporated during V 0 assembly (Malkus et al., 2004) . To determine the subcellular locations in which mammalian VMA21 acts, we stained C2C12 myoblasts and COS7 cells with VMA21 and organelle-specific antibodies. VMA21 localizes in the ER, and not in mitochondria, peroxisomes, or lysosomes. It is not present in Golgi or trans-Golgi networks. However, it does localize in the ER-Golgi intermediate compartment (ERGIC) and in COPII vesicles (Figure 4 ). VMA21 lacks a dilysine ER return signal. Consistent with this, VMA21 does not localize on COPI, the ER return vesicle ( Figure 4A ). In summary, VMA21 follows part of the route of Vma21p, traveling from ER to ERGIC but not beyond, and not back to ER, at least not via COPI vesicles. 
Decreased, Increased, and Excessive Autophagy in XMEA Autophagy is the degradation of long-lived proteins and other cell components. It is composed of three processes with a common final stage, digestion at low pH by lysosomal hydrolases. In chaperone-mediated autophagy, proteins are taken into the lysosome via receptors. In microautophagy, they are engulfed by the lysosome. In macroautophagy, an isolation membrane forms in the cytoplasm, surrounds targeted proteins and other constituents, and fuses with lysosomes. The transitional structure prior to merger with lysosomes is called the autophagosome, and the final organelle the autolysosome. Macroautophagy is the largest contributor to autophagy and is the system that expands to compensate for insufficiencies in the nonmacroautophagic processes, or to meet increased autophagic demands such as during starvation ( On the basis of our finding of decreased V-ATPase activity in XMEA, we predicted that XMEA cells have increased lysosomal pH and a resultant partial block in the common final degradative stage of autophagy. To test this, we first measured lysosomal pH. We incubated fibroblasts with Oregon green dextran overnight, during which the dextran is endocytosed to the lysosome, where it fluoresces with an intensity proportional to pH and emits two wavelengths around an isobestic point, i.e., fluorescence intensity at one wavelength is inversely proportional to the intensity at the other and their ratio corrects for focal plane artifacts ( Figure S6 ) (Paroutis et al., 2004) . pH of patient lysosomes was 0.5 units higher, i.e., three times less [H + ], than that of controls ( Figure 5A ). Next, we measured autophagy by quantifying the degradation of long-lived proteins. We cultured lymphoblasts and fibroblasts for 48 hr with radioactive cysteine and methionine. After washing, we chased protein degradation by measuring the trichloroacetic acid (TCA)-soluble fraction of total 
radioactivity for 72 hr. Three types of chase media were used to allow calculation of total autophagy, macroautophagy, and nonmacroautophagy: routine media, media with lysosomal protease inhibitors (NH 4 Cl and leupeptin), and media containing 3-methyl adenine, a specific macroautophagy inhibitor. We found that in controls and patients, approximately half of long-lived protein degradation was macroautophagic and half was through nonmacroautophagy, that total long-lived protein degradation in patients was 25 to 50% lower than that in controls, and that this reduction in autophagic flux was due approximately equally to reductions in macro and nonmacroautophagies (Figures 5B and 5C) . In separate experiments, proteolysis of short-lived proteins, which is largely proteasomal and nonlysosomal, was unaffected (data not shown).
We reasoned that the block in autophagy should induce an upregulation of macroautophagy. Beclin-1 is a pivotal early component of the macroautophagy pathway. Its increased amount and interaction with the class III PI3 kinase hVps34 activate and upregulate the pathway (Cao and Klionsky, 2007) . LC3 is a cytosolic protein that upon activation of macroautophagy converts from its LC3-I (18 kD) to its LC3-II (16 kD) form to function in the isolation membrane that forms the autophagosome (Mizushima et al., 2002) . Western blot and immunoprecipitation studies in lymphoblasts and fibroblasts showed major increase in beclin-1, beclin-1-hVps34 interaction, and LC3-II in XMEA patients ( Figure 5D ). LC3 was also increased at the transcriptional level, 2-fold. The mRNA of a second early macroautophagy gene tested, ATG12, was increased 10-fold ( Figure 5E ). These results confirm that macroautophagy is upregulated in XMEA. We next tested the phosphorylation status of the p70S6 kinase and found it to be dephosphorylated ( Figure 5D ). This indicates that of the several pathways to autophagic upregulation, the mTOR pathway is activated (Cao and Klionsky, 2007) . This pathway is principally activated by reduced levels of cellular amino acids. We measured the concentration of free amino acids in XMEA cells and found it to be $50% lower than that in controls ( Figure 5F ).
Autolysosomes are evanescent structures that rapidly degrade their contents, and few are observed in normal cells at any one time. We asked whether in XMEA the upregulation of macroautophagy, coupled with delayed degradation of autolysosomal contents, results in increased autolysosomes. Electron and immunofluorescence microscopy showed in all XMEA lymphoblasts and fibroblasts, as well as in their blood leukocytes and platelets, a proliferation of normal autolysosomes ( Figures 6A and 6B ). Ninety percent of these cells were otherwise morphologically normal. However, in 10%, the numerous autolysosomes were observed merging one with the other, forming giant vacuoles identical to the diseasedefining autophagic vacuolation of XMEA skeletal muscle ( Figures 6C-6E ). These observations show that XMEA cells other than muscle have the same autophagic vacuolation as muscle cells, though in a smaller proportion (10% versus 40%-80%). They also show a continuum from upregulated autophagy to proliferation of autolysosomes to autophagic vacuolation.
Finally, we aimed to determine whether VMA21 mutations cause the above succession of events through their 
downregulation of autophagy, and not through a separate mechanism, i.e., we asked whether decreased autophagy by 25% to 50% alone elicits macroautophagy and autophagic vacuolation. Leupeptin is a pH-independent inhibitor of lysosomal hydrolases. First, we identified 30 mM as the leupeptin concentration needed to decrease long-lived protein degradation by 37% ( Figure S7 ). Lymphoblasts and fibroblasts from normal subjects incubated with this concentration of leupeptin exhibited mTOR-dependent upregulation of macroautophagy autolysosome proliferation, mergers of autolysosomes, and autophagic vacuolation ( Figures 5D and 6F ), identical to XMEA.
Restoring VMA21 mRNA Levels Corrects the XMEA Autophagic Disturbance As final proof that decreased VMA21 is the cause of the autophagic disturbance in XMEA, we raised the levels of VMA21 mRNA in (B) Chase of lysosome-dependent long-lived protein degradation in lymphoblasts. In this and next panel, chase media contained MG-132 to eliminate proteasomal contribution. Also, any other nonlysosomal proteolysis-measured as protein degradation in cells cultured in parallel in media with NH 4 Cl/leupeptin-was subtracted from total proteolysis to obtain the data shown. Nonlysosomal proteolysis was negligible, <3% of lysosomal, and unvarying. P1, P2, etc. are different XMEA patients. (C) I: Thirty-six hour time points from (B). II: Cells cultured with the specific macroautophagy inhibitor 3MA; measures the nonmacroautophagic portion of lysosome-dependent protelysis. III: Difference between I and II, i.e., between total lysosome-dependent proteolysis and its nonmacroautophagic portion; measures the macroautophagic portion of total lysosome-dependent proteolysis. Error bars represent the mean ± standard deviation of three independent repeats. (D) Macroautophagic upregulation in XMEA cells and low-dose leupeptin treated non-XMEA cells. (a) Coimmunoprecipitation of hVps34-beclin-1 interaction complexes with the beclin-1 monoclonal antibody in control and patient cells was performed. Immunoprecipitates were run on SDS-PAGE, and western blot with polyclonalrabbit anti-beclin-1 and hvps34 antibody shows increase in beclin-1 and hvps34-beclin-1 complexes in patients and leupeptin-treated cells. GAPDH was used as loading control and anti-HA antibody as immunoprecipitation control. (b) Phosphorylation status of the p70S6 kinase was determined with phospho-specific and total p70S6 kinase antibodies; p70S6 kinase is less phosphorylated in patients and leupeptin-treated cells. Total p70S6 kinase levels remain similar in patients, leupeptin-treated cells, and controls. (c) An immunoblot of LC3 is shown; total LC3 and the LC3-II isoform are increased in patients and leupeptin-treated cells. (E) Quantitative RT-PCR of the LC3B gene shows 1.5-to 2-fold increased expression in patients, and of the ATG12 gene a 10-fold increase. Expression of the b-actin gene was used as control. Error bars represent the mean ± standard deviation from three independent experiments performed in triplicate. (F) Quantitation of intracellular free aminoacids. White bars, lymphoblasts; gray bars, fibroblasts; C, normal cells; S, normal cells in starvation condition (Hanks balanced salt solution for four hours). Note that XMEA cells maintain themselves at even lower free amino acid concentration than do amino acid-starved normal cells. Error bars represent the mean ± standard error on triplicate readings.
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XMEA fibroblasts by retrovirus infection and stable expression of VMA21. Cells treated in this fashion exhibited normalization of V-ATPase assembly and activity, lysosomal pH, long-lived protein degradation, intracellular amino acid levels, beclin-1 levels, beclin-1-hVps34 interaction, and LC3 isoforms. Autolysosomes and autophagic vacuoles were no longer present and cells returned to normal morphology ( Figures 7A-7H ).
Not All V-ATPase-Dependent Functions Are Affected in XMEA Multiple cell systems other than autophagy require V-ATPases, none of which appears to be affected to a clinical extent in our patients. We studied one of these systems, the maturation of lysosomal enzymes, a three-step process that depends on successively lower pH. We examined hexosaminidases A and B and cathepsin D in XMEA fibroblasts and found the maturations of all three to be identical to controls (Figures S8 and S9 ).
DISCUSSION
XMEA mutations are hypomorphic alleles that reduce the amount of VMA21, in most cases by decreasing mRNA splicing efficiency. Only skeletal muscle is clinically affected, and only in males. Female carriers are unaffected, likely because muscle is a syncytium and half of the nuclei will produce normal amounts of VMA21 mRNA. We show that VMA21 is the human ortholog of the yeast V-ATPase chaperone Vma21p and that reduced VMA21 results in misassembly of the V-ATPase, decreased numbers of V-ATPases, and reduced cellular V-ATPase activity to 10%-30% of normal. Several other genetic diseases affecting V-ATPases have been described. In all of these diseases, mutations affect specific V-ATPases in particular cellular locations and are lossof-function mutations that completely eliminate the particular V-ATPase. For example, mutations in the gene encoding the a2 isoform of subunit ''a'' affect certain Golgi and early endosome V-ATPases in certain tissues, but not lysosomal or other V-ATPases (causing developmental delay with wrinkled skin; Kornak et al. [2008] ). Mutations in a3 affect only V-ATPases on osteoclast plasma membranes (causing osteopetrosis; Frattini et al. [2000] ). Mutations in a4 affect only renal and inner ear plasma membrane V-ATPases (causing renal tubular acidosis and deafness; Karet et al. [1999] ). To our knowledge, XMEA is the first disease in which total, not local, cellular V-ATPase activity is affected. On the other hand, XMEA mutations do not completely eliminate V-ATPase activity. XMEA patients do not exhibit neurodevelopmental delay or clinically manifest skin and bone abnormalities, acidosis, or hearing loss, indicating that for the specialized a2-, a3-, and a4-containing V-ATPases the reduced V-ATPase assembly in XMEA does not reach a clinical threshold.
The reduced V-ATPase activity in XMEA results in a rise in lysosomal pH from 4.7 to 5.2. Maturations of three lysosomal enzymes tested are not affected. Their pH-dependent modifications are normal, and the final enzymes have normal activities in vitro. In vivo, though, these enzymes are expected to have lowered activity in patient lysosomes because of their raised pH. Hexosaminidase, for example, is known to be 50% less active at pH 5.2 than at pH 4.7 (Sharma et al., 2001) . Not surprisingly, this degree of hexosaminidase downregulation is tolerated by XMEA patients who, like Tay-Sachs disease carriers who also have 50% reduced hexosaminidase, do not have Tay-Sachs symptoms. Other individual lysosomal enzymes are likely similarly subclinically downregulated.
Autophagy, the collective activity of lysosomal enzymes involved in the degradation of long-lived proteins, also is reduced. The extent of this reduction in patient cell lines is certainly greater than the 50% we recorded, because, as we showed, it is coupled with a compensatory upregulation of macroautophagy, with which cells achieve the 50% level. The outcomes of reduced autophagy are reduced recycling of 
defective and unneeded proteins, and reduced generation of amino acids through this recycling. The cell can ill afford to fully replace the amino acid shortfall with extrinsic amino acids from culture medium or nutrition, because continual reliance on external instead of recycled sources would result in continuing net surpluses and ever-increasing accumulations of unneeded proteins, which would increasingly tax already strained autophagy. The cell therefore needs to find a new homeostasis, with reduced cytoplasmic free amino acids, which we show is the case in XMEA. Reduction of amino acids is the most potent inducer of macroautophagy, through inhibition of the mTOR kinase. mTOR reciprocally regulates macroautophagy and protein synthesis. Inhibited mTOR dephosphorylates the p70S6 kinase (as is the case in XMEA, Figure 5D ), which reduces protein synthesis, and expands macroautophagy through enhanced beclin-1-hVps34 binding ( Figure 5D ) (Cao and Klionsky, 2007) . Increased macroautophagy means increased formation of autolysosomes, but in XMEA each new autolysosome formed faces a degradative block and is slow to progress and disappear. Increased formation coupled with delayed progression results in vast numbers of autolysosomes, in some cells fusing together and forming giant autophagic vacuoles and autophagic vacuolation identical to the disease in muscle that gives XMEA its name, ''excessive autophagy.'' The percent of cells in patient cell lines and blood cells that are thus diseased, i.e., vacuolated, is $10%. The remaining 90%, except for the increased number of autolysosomes, show no pathological changes. This indicates that in 90% of cells, the autophagic block is compensated by the increased macroautophagy, but that this compensation is precarious, with some cells, 10%, transitioning into autophagic vacuolation. In skeletal muscle, the percent vacuolated cells is much greater, 40% to 80%, which may explain why clinical symptoms are present only in this tissue.
So far, we posited that the autophagic block is a consequence of decreased V-ATPase activity. The possibility exists that it is instead caused by some other effect of the VMA21 mutations unrelated to their effect on the V-ATPase. This is ruled out by the following. Bafilomycin is a specific inhibitor of the V-ATPase. At concentrations above 10 nM, it completely inhibits V-ATPase activity. Between 0.3 and 10 nM, it reduces V-ATPase activity to 10% to 40% of normal (Drose and Altendorf, 1997) , similar to the V-ATPase activity in XMEA. In the literature are several reports in which, as controls for other experiments, cells of various types were treated with these low concentrations of bafilomycin. This resulted in decreased autophagy, mTOR-dependent activation of macroautophagy, and autolysosome proliferation and autophagic vacuolation (Ostenfeld et al., 2008; Shacka et al., 2006) , which upon review are identical to what we observe in XMEA. V-ATPase block therefore has the same autophagic outcome as VMA21 mutations, confirming that the mutations cause the autophagic defect via their effect on the V-ATPase. The literature also substantiates that decreased V-ATPase causes the autophagic block through raising lysosomal pH, and not through some alternate mechanism. Chloroquine and siramesine are agents that accumulate in lysosomes, raise lysosomal pH, block autophagy, and lead to mTOR-dependent macroautophagy and autophagic vacuolation (Ostenfeld et al., 2008; Shacka et al., 2006; Stauber et al., 1981) . Chloroquine is in clinical use as an antimalarial and antirheumatic agent. Prolonged exposure to chloroquine causes an iatrogenic disease affecting only skeletal muscle clinically, despite the fact that lysosomes of all tissues are affected. This disease is an autophagic vacuolar myopathy that is so similar to XMEA that it is its main pathological differential diagnosis (Kalimo et al., 1988; Minassian et al., 2002; Stauber et al., 1981) . The similarity between the effect on autophagy of decreased V-ATPase, choloroquine, and siramesine, and between XMEA and chloroquine myopathy, indicates that the autophagic block caused by decreased V-ATPase is through raising lysosomal pH. Finally, the autophagic block is the cause of the macroautophagic upregulation and autophagic vacuolation, as demonstrated in this study by blocking the last stage of autophagy, through direct inhibition of lysosomal proteases (to the same degree as in XMEA) and obtaining the same mTOR-dependent macroautophagic upregulation and diseasedefining autophagic vacuolation as in XMEA.
Apart from chloroquine myopathy, the differential diagnosis of XMEA includes one disease with known cause (Danon disease; LAMP2 deficiency) (Nishino et al., 2000) . LAMP2 participates in chaperone-mediated autophagy, lysosome biogenesis, lysosome-autophagosome fusion, and lysosome locomotion along microtubule tracts toward phagosomes (Malicdan et al., 2008) . Defects in any or all of these could reduce autophagy and underlie the vacuolation. In fact, in the mouse model of this disease, organs with reduced autophagy exhibit the autophagic vacuolation (Tanaka et al., 2000) .
Why muscle is principally affected in Danon disease, chloroquine myopathy, and XMEA is not known. In XMEA, this is not due to less muscle V-ATPase activity, as we found no difference in V-ATPase activity between muscle and other cells. We theorize that the expanded vacuolation in muscle is due to a particularity of macroautophagy in this tissue, namely a vastly greater macroautophagic response to decreased amino acids compared to other tissues, the purpose of which is to break itself down to supply amino acids to other organs (Mizushima et al., 2004; Scornik et al., 1997) . This is mediated through mTOR and through a second much more potent pathway unique to muscle, the FoxO3 pathway (Mammucari et al., 2008) . This drastic macroautophagic response is highest in type II fasttwitch fibers (Li and Goldberg, 1976; Mizushima et al., 2004) , which are the fibers with the highest degree of autophagic vacuolation and atrophy in XMEA (Chabrol et al., 2001; Kalimo et al., 1988; Minassian et al., 2002; Villanova et al., 1995) . In fibroblasts and other cell types we studied, the macroautophagic response to blocked autophagy is ''excessive'' (autolysosomes merging into autophagic vacuoles) in $10% of cells. In muscle, greater macroautophagic response to the same autophagic block could underlie the greater autophagic vacuolation (40%-80%) and defining pathology of the disease.
Do the assembly processes directed by VMA21 in humans parallel those of Vma21p in yeast? Yeast c, c 0 , and c 00 subunits compose the rotating cylinder of the V 0 sector of the V-ATPase and are homologous proteins with 32%-56% sequence identity. Vma21p interacts directly only with c 0 and not with other V 0 proteins, indicating that its assembling function is mediated through c 0 (Malkus et al., 2004 (Forgac, 2007) . We show that VMA21 interacts directly only with c 00 , indicating that VMA21 acts via c 00 . Human c 00 has only 31% amino acid identity and 50% similarity to yeast c 0 , consistent with the extensive sequence divergence of VMA21 from Vma21p (22% identity). On the other hand, c 00 is strongly conserved from yeast to man (60% identity). It is possible that human VMA21 is able to rescue yeast vma21D, despite its great divergence from Vma21p, not by acting through the substrate of Vma21p, c 0 , but through the yeast ortholog of its own substrate, c 00 . In yeast, Vma21p accompanies the nascent V-ATPase on COPII vesicles to the Golgi and returns to the ER on COPI vesicles (Malkus et al., 2004) . VMA21 also travels on COPII vesicles, but it goes only as far as the ERGIC and does not return via COPI. The systems therefore diverged, and the fate of VMA21 after ERGIC is unknown. Possibly it simply drifts back to the ER through the continuousness of ERGIC and ER.
This work describes the clinical outcome at the cusp of tolerable reduction in V-ATPase, with implications on common diseases. In malaria, the parasite inserts a V-ATPase into the erythrocyte membrane, conferring itself optimal pH, and increased V-ATPase activity is an important component of HIV infection, osteoporosis, and cancer metastasis (Forgac, 2007) . Our XMEA patients show that the safety margin of reducing V-ATPase activity in humans is wide, increasing the potential to utilize bafilomycin-related compounds, or RNAi against VMA21, as possible therapies.
EXPERIMENTAL PROCEDURES

Mutation Identification
This study was approved by the Research Ethics Board of the Hospital for Sick Children, and informed consent was obtained from all subjects. Primer pairs to amplify VMA21 exons and flanking sequences can be found in Table S2 
Complementation Assay
Saccharomyces cerevisiae BY4742 wild-type strain (MATa; his3D1; leu2D0; lys2D0; ura3D0) and vma21D mutant (BY4742; Mata; his3D1; leu2D0; lys2D0; ura3D0; YGR105w::kanMX4) were obtained from Euroscarf. LOC203547 was cloned into yeast expression plasmid pCADNS under alcohol dehydrogenase (ADH) promoter, terminator, and transformed into BY4742 and vma21D. Transformants were selected on synthetic complete media without leucine and assayed for viability on medium containing 10 mM Cacl2, YPD (pH 7.5; alkaline conditions), and ability to grow on glycerol as sole carbon source.
V-ATPase Assays
Total protein was measured with the Bradford assay and a bovine serum albumin (BSA) standard curve. Hydrolysis of ATP by V-ATPase was measured by the bafilomycin A1-sensitive method. Microsomal pellets were thawed on ice and suspended in ATPase buffer (10 mM HEPES-Tris [pH 7], 5 mM MgCl2, 50 mM KCl, 10 mM NaN 3 , 1 mM levamisole-10 mM NaF, 0.7 mg/ml leupeptin, 0.7 mg/ml pepstatin A, 48.72 mg/L phenylmethylsulphonyl fluoride [PMSF] ) to a protein concentration of 0.75-1.75 mg/ml (see the Supplemental Experimental Procedures for subcellular fractionation method). The reaction mix contained 1 mM ATP substrate, 3 mg total protein samples, 5 mM valinomycin, 5 mM nigericin, 1 mM orthovanadate, 10 mg/mL oligomycin in ATPase buffer made to 70 ml final volume and incubated in presence and absence of 10 nM bafilomycin for 30 min at 37 C. ATP hydrolysis was terminated with 13% SDS and 100 mM ethylenediaminetetraacetic acid (EDTA). Control reactions were done in order to correct any nonenzymatic hydrolysis of ATP or orthophosphate contamination from reagents by addition of the stop solution prior to ATP substrate addition. The reaction was initiated by addition of Taussky-Shorr color reagent (0.5% w/v FeSO 4 , 0.5% w/v ammonium molybdate, and 0.5 M H 2 SO 4 ). The reaction was incubated for 20 min at room temperature, and inorganic phosphate (Pi) was measured by absorbance at 650 nm. A standard calibration curve was generated with Pi standards (0, 2.5, 5, 10, 25, 50, 100, 150 nmole). Mean values and standard deviation were calculated from three independent assay repeats done in triplicate.
Determination of Lysosomal pH
Fibroblasts were seeded on 25 mm circular glass coverslips and grown to confluence in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS; Wisent) at 37 C, 5% CO 2 . At confluence, cells were washed twice with PBS and serum-starved by addition of DMEM containing 2% FBS for 40 min. Lysosomes were loaded overnight with 0.5 mg/mL dextran-coupled Oregon Green 514 (Molecular Probes) in DMEM supplemented with 10% FBS, chased for 2 hr in DMEM (10% FBS), and washed to remove residual dextran. Ratiometric fluorescence microscopy was performed with a Leica DMIRB microscope with 1003 (1.4 NA) oil objective. Fluorescence images were acquired at excitation wavelengths of 440 ± 10 nm and 490 ± 10 nm. Image acquisition and analysis was performed with MetaMorph software (Universal Imaging). Regions of interest (ROIs), representing late endosomes/lysosomes as resolved by light microscopy, were defined as areas above a certain fluorescence threshold in the 490 nm excitation channel. Mean intensity ratio between 490 and 440 nm excitation channels was calculated for each ROI, and mean ratio weighted by ROI size was then calculated for each imaged fibroblast. Calibration curves were obtained after 4 min equilibration in nigericin (5 mm) containing MES buffers (30 mM NaCl, 130 mM KCl, 30 mM MgCl2, 25 mM MES, 20 mM glucose) with different pH values adjusted between pH 3.0 to 7.0. Ratios were converted to pH by using the calibration curve fitted to a sigmoidal equation. At least six lysosomes within the same cell were covered, and the experiment was repeated six times for significance. Redivue in vitro cell labeling mix for 48 hr at 37 C and washed and maintained in complete medium with excess of unlabeled met and leu for 48 hr. Aliquots of media and cells taken at different times were precipitated in TCA, and proteolyses were measured. Total radioactivity incorporated in cellular proteins was determined in triplicate samples as the amount of acid-precipitable radioactivity. Proteolysis was calculated as the percent of acid-precipitable radioactivity (protein) transformed into acid-soluble radioactivity (amino acids and peptides) at the different time points analyzed. Values were expressed as the percent of protein degraded. In separate sets, the above proteolysis experiments were performed in the presence of 15 mM NH 4 Cl and 100 mM leupeptin or 10 mM 3-methyladenine (3MA) in the culture medium during the chase. The
